ACADIA Pharmaceuticals Inc. (ACAD) Stock: What Does the Chart Say Tuesday?

Overall market sentiment has been neutral on ACADIA Pharmaceuticals Inc. (ACAD) stock lately. ACAD receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

ACADIA Pharmaceuticals Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ACAD!

See Full ACAD Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ACAD Stock Today?

ACADIA Pharmaceuticals Inc. (ACAD) stock is trading at $17.05 as of 4:00 PM on Tuesday, May 17, a gain of $0.45, or 2.71% from the previous closing price of $16.60. The stock has traded between $16.61 and $17.23 so far today. Volume today is 1,399,110 compared to average volume of 1,790,492. To screen for more stocks like ACADIA Pharmaceuticals Inc. click here.

More About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Click Here to get the full Stock Report for ACADIA Pharmaceuticals Inc. stock.